Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The changing landscape of induction therapy for newly diagnosed multiple myeloma

Elias Mai • 9 Jun 2022
EHA 2022
Multiple Myeloma Antibodies Bortezomib Dexamethasone Isatuximab Lenalidomide
CASSIOPEIA

Elias Mai, MD, University Hospital Heidelberg, Heidelberg, Germany, outlines new agents added to induction strategies in patients with newly diagnosed transplant-eligible multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Consulting or Advisory Role, Honoraria, Research Funding, and Travel Accommodations and Expenses – Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi and Takeda.

More from Elias Mai

1:03
Advantages and applications of mass spectrometry in multiple myeloma
Elias Mai • 25 Apr 2023
1:31
The role of daratumumab in combination with lenalidomide as maintenance therapy in NDMM post-autoSCT
Elias Mai • 25 Apr 2023
1:05
Optimizing the treatment of transplant-eligible NDMM: using quadruplets in induction & consolidation
Elias Mai • 25 Apr 2023
0:49
An update on GMMG HD7: Isa-RVd vs RVd & lenalidomide-isatuximab vs lenalidomide maintenance in NDMM
Elias Mai • 9 Jun 2022

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals